Altın, Cihan
Loading...
Profile URL
Name Variants
Altin, Cihan
Altin, C.
Altin, C.
Job Title
Email Address
cihan.altin@ieu.edu.tr
Main Affiliation
09.02. Internal Sciences
Status
Current Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
SDG data is not available
Documents
67
Citations
550
h-index
13
Documents
83
Citations
408
Scholarly Output
15
Articles
9
Views / Downloads
2/0
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
22
Scopus Citation Count
19
WoS h-index
3
Scopus h-index
2
Patents
0
Projects
1
WoS Citations per Publication
1.47
Scopus Citations per Publication
1.27
Open Access Source
10
Supervised Theses
0
| Journal | Count |
|---|---|
| Anatolıan Journal of Cardıology | 3 |
| Cardıovascular Drugs And Therapy | 2 |
| European Journal of Heart Failure | 2 |
| Diagnostics | 1 |
| Esc heart failure | 1 |
Current Page: 1 / 3
Scopus Quartile Distribution
Competency Cloud
15 results
Scholarly Output Search Results
Now showing 1 - 10 of 15
Conference Object Real-World Use of Empaglifozin and Dapaglifozin in Patients With Heart Failure(Wiley, 2024) Kocabas, U. Uumut; Yavuz, V.; Altin, C.; Kaplan, M.; Oztekin, G. M. Yilmaz; Dogdus, M.; Murat, S.[No abstract available]Article Diagnostic Potential of Ctrp5 and Chemerin for Coronary Artery Disease: a Study by Coronary Computed Tomography Angiography(Mdpi, 2025) Okan, Taha; Altin, Cihan; Topaloglu, Caner; Doruk, Mehmet; Yilmaz, Mehmet BirhanBackground/Objectives: As an endocrine organ, adipose tissue produces adipokines that influence coronary artery disease (CAD). The objective of this study was to assess the potential value of CTRP5 and chemerin in differentiating coronary computed tomography angiography (CCTA)-confirmed coronary artery disease (CAD) versus non-CAD. Secondarily, within the CCTA-confirmed CAD group, the aim was to investigate the relationship between the severity and extent of CAD, as determined by coronary artery calcium score (CACS), and the levels of CTRP5 and chemerin. Methods: Consecutive individuals with chest pain underwent CCTA to evaluate coronary artery anatomy and were divided into two groups. The CCTA-confirmed CAD group included patients with any atherosclerotic plaque (soft, mixed, or calcified) regardless of calcification, while the non-CAD group consisted of individuals without plaques on CCTA, with zero CACS, and without ischemia on stress ECG. Secondarily, in the CCTA-confirmed CAD group, the severity and extent of CAD were evaluated using CACS. Blood samples were collected and stored at -80 degrees C for analysis of CTRP5 and chemerin levels via ELISA. Results: Serum CTRP5 and chemerin levels were significantly higher in the CAD group compared to the non-CAD group (221.83 +/- 103.81 vs. 149.35 +/- 50.99 ng/mL, p = 0.003 and 105.02 +/- 35.62 vs. 86.07 +/- 19.47 ng/mL, p = 0.005, respectively). Receiver operating characteristic (ROC) analysis showed that a CTRP5 cutoff of 172.30 ng/mL had 70% sensitivity and 73% specificity for identifying CAD, while a chemerin cutoff of 90.46 ng/mL had 61% sensitivity and 62% specificity. A strong positive correlation was observed between CTRP5 and chemerin, but neither adipokine showed a correlation with the Agatston score, a measure of CAD severity and extent, nor with coronary artery stenosis as determined by CCTA. Conclusions: CTRP5 and chemerin were significantly elevated in the CCTA-confirmed CAD group compared to the non-CAD group, with CTRP5 showing greater sensitivity and specificity. However, neither adipokine was linked to CAD severity and extent, differing from findings based on invasive coronary angiography (ICA). CTRP5 may serve as a promising "all-or-none biomarker" for CAD presence.Article Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: the Follow-Up Results of the Anatolia-Af Study(Wiley, 2025) Kocabas, Umut; Ergin, Isil; Sonmez, Sadi Can; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim Halil; Kivrak, TarikObjectiveThe main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real-world setting.MethodsThe present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all-cause mortality.ResultsA total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12-month follow-up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all-cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.ConclusionThe follow-up data from the ANATOLIA-AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.Article Citation - WoS: 5Citation - Scopus: 2Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: the Anatolia-Af Study(Springer, 2022) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, CihanPurpose Inappropriate dosing of direct oral anticoagulants is associated with an increased risk of stroke, systemic embolism, major bleeding, cardiovascular hospitalization, and death in patients with atrial fibrillation. The main goal of the study was to determine the prevalence and associated factors of inappropriate dosing of direct oral anticoagulants in real-life settings.Methods This study was a multicenter, cross-sectional, observational study that included 2004 patients with atrial fibrillation. The study population was recruited from 41 cardiology outpatient clinics between January and May 2021. The main criteria for inappropriate direct oral anticoagulant dosing were defined according to the recommendations of the European Heart Rhythm Association.Results The median age of the study population was 72 years and 58% were women. Nine-hundred and eighty-seven patients were prescribed rivaroxaban, 658 apixaban, 239 edoxaban, and 120 dabigatran. A total of 498 patients (24.9%) did not receive the appropriate dose of direct oral anticoagulants. In a logistic regression model, advanced age, presence of chronic kidney disease and permanent atrial fibrillation, prescription of reduced doses of direct oral anticoagulants or edoxaban treatment, concomitant use of amiodarone treatment, and non-use of statin treatment were significantly associated with potentially inappropriate dosing of direct oral anticoagulants.Conclusion The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.Correction Citation - WoS: 1Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: the Anatolia-Af Study (dec, 10.1007/S10557-022-07409-w, 2022)(Springer, 2023) Kocabas, Umut; Ergin, Isil; Yavuz, Veysel; Murat, Selda; Ozdemir, Ibrahim; Genc, Omer; Altin, Cihan[Abstract Not Available]Article Exploring Hypertension Awareness in Physicians: A Cross-Sectional Study From Turkey(Termedia Publishing House Ltd, 2025) Taskin, Ugur; Fici, Francesco; Altin, Cihan; Dogdus, Mustafa; Mammadov, Ganbar; Topaloglu, Caner; Tengiz, IstemihanIntroduction: Hypertension is a significant public health concern and a contributor to cardiovascular conditions. Although physicians are essential in preventing and managing hypertension, limited research has been conducted on their own awareness of the condition. Aim: We aimed to examine the prevalence and awareness of hypertension among doctors in Turkey and identify relevant demographic and behavioral risk factors. Material and methods: A cross-sectional study was carried out with 178 physicians aged 25 to 64, randomly chosen from 35 healthcare institutions in 24 cities across Turkey. Data collection involved a structured questionnaire that examined hypertension awareness, sociodemographic details, and cardiovascular risk factors, complemented by standardized blood pressure assessments and body measurements. Hypertension was identified based on a systolic blood pressure of >= 140 mm Hg and/or a diastolic pressure of >= 90 mm Hg, self-reported diagnosis, or the use of antihypertensive drugs. Results: The overall prevalence of hypertension was 15.7%, with a significantly higher rate among males (20.2%) than females (7.8%) (p = 0.03). Age was a strong predictor, as individuals over 40 years had a markedly higher hypertension prevalence (27.9%) compared to those under 40 (4.3%) (p < 0.001). Body mass index (BMI), smoking, and physical inactivity were also significantly associated with hypertension. Among hypertensive doctors, awareness was 78.5%, though it did not show significant differences based on gender, BMI, or comorbidities. Conclusions: Despite relatively high awareness levels, hypertension remains prevalent among medical professionals, particularly in older and male doctors. Targeted strategies, such as routine screenings and lifestyle intervention programs, are essential to improve hypertension prevention and management in this population.Article Citation - WoS: 13Citation - Scopus: 14Real-World Data on Empagliflozin and Dapagliflozin Use in Patients With Heart Failure: the Red-Heart Study(Wiley Periodicals, Inc, 2024) Kocabaş, Umut; Ergin, Işıl; Yavuz, Veysel; Altın, Cihan; Kaplan, Mehmet; Oztekin, Guelsuem Meral Yilmaz; Dogdus, MustafaAims: We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results: The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions: The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.Article Pentraxin 3: a Marker for the Presence and Severity of Coronary Artery Disease(Kare Publ, 2025) Okan, Taha; Topaloglu, Caner; Altin, Cihan; Doruk, Mehmet; Yilmaz, Mehmet BirhanObjective: Atherosclerosis, a major contributor to coronary artery disease (CAD), is characterized by chronic arterial inflammation. Pentraxin 3 (PTX-3), a biomarker of inflammation, serves as an indicator of both atherosclerosis and the progression of CAD. The aim of this study was to investigate the association between PTX-3 levels and the presence and severity of CAD, as determined by coronary computed tomography angiography (CCTA). Method: In this study, 94 participants (54 with CAD and 40 controls) underwent CCTA and coronary artery calcium scoring (CACS) using computed tomography. PTX-3 levels were measured using the enzyme-linked immunosorbent assay (ELISA) method. CAD patients were categorized based on CCTA findings and furthersubdivided into three groups according to their CACS: Group I (CACS < 100), Group II (CACS 100-299), and Group III (CACS >= 300). Results: Serum PTX-3 levels were significantly higher in the CAD group. A PTX3 cut-off value of 5.80 ng/mL predicted CAD with 68% sensitivity and 66% specificity. A strong positive correlation was observed between CACS and PTX-3 levels (r = 0.521, P < 0.001). In high-risk patients with a CACS >= 300, PTX-3 levels were significantly higher than those in low- and intermediate-risk groups a CACS < 300. However, no significant difference in PTX-3 levels was observed between the normal coronary group and the low- and intermediate-risk groups. Furthermore, no correlation was found between the degree of coronary artery stenosis and PTX-3 levels. Conclusion: Pentraxin 3 might serve as a valuable biomarkerforthe diagnosis and severity of CAD.Article Gebelikte Uterin Arter Doppler ve Epikardiyal Yağ Kalınlığının Ölçülmesi ve Perinatal Sonuçların Karşılaştırılması(2022) Balcı, Serdar; Altın, CihanAmaç: Yetersiz plasental gelişim, çeşitli sitokinlerin üretimine neden olarak, bir yandan fetal büyüme geriliğine ve diğer yandan mater? nal endotel hasarına yol açar. Preeklampsinin patogenezinde rol oynadığı düşünülen bu sitokinler, hem uteroplasental vasküler sistem? de hem de maternal dolaşımda endotelyal disfonksiyona neden olur. Viseral yağlanma, enflamatuvar hastalıklara karşı immün yanıta aracılık eden proenflamatuvar ve proaterojenik sitokinleri salgılar. Bilateral uterin arter Doppler değerleri ve epikardiyal yağ kalınlığı, olumsuz gebelik sonuçlarının yeni belirleyicileri olabilir. Gereç ve Yöntem: 89 gebe kadın çalışmaya dahil edildi. Gebeliğin ikinci üç ayında bilateral uterin arter Doppler akımları ve epikardiyal yağ kalınlığı ölçüldü. Olumsuz gebelik sonuçlarının en iyi tahmini için alıcı işlem karakteristiği eğrisi analizi kullanıldı. Bulgular: 62 hasta herhangi bir sorun olmadan gebeliği tamamlarken, 27 hastada düşük doğum ağırlığı, preterm doğum, prematüre doğum ve gebeliğe bağlı hipertansif hastalıklar saptandı. Gebelik sonucu kötü olan hastalarda epikardiyal yağ kalınlığı kontrol grubuna göre anlamlı olarak daha yüksek bulundu (5,78±1,74 mm ve 4,99±0,90 mm, p=0,006). Alıcı işlem karakteristiği eğrisi analizinde; epi? kardiyal yağ kalınlığı >4,30 mm, kötü gebelik sonucunun tanısını öngörmede %74,1 özgüllük ve %74,2 duyarlılığa sahipti. Bilateral ute? rin arter Doppler ölçümleri için çizilen alıcı işlem karakteristiği eğrilerinde anlamlı bir sonuç alınamadı. Sonuç: Epikardiyal yağ kalınlığındaki artış, gebeliğin hipertansif hastalıkları, yetersiz plasentasyon ve buna bağlı fetal büyüme geriliği, preterm doğum, prematüre doğum veya düşük doğum ağırlığı gibi perinatal olumsuz sonuçları tetikleyebilir. Epikardiyal yağ kalınlığı, metabolik sendromun yeni bir kriteridir ve insülin direnci, hipertansiyon, dislipidemi ve koroner arter hastalıkları ile ilişkisi gösterilmiş? tir. Yüksek riskli gebeliklerin epikardiyal yağ kalınlığı gibi basit ama öngörülebilir yöntemlerle taranmasının maternal ve fetal morbidi? teyi ve mortaliteyi azaltmada önemli bir rolü olabileceği düşünülmektedirArticle Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye(Kare Publ, 2024) Türk, Uğur Önsel; Kocabaş, Umut; Özçalık, Emre; Kıvrak, Tarık; Altın, CihanAmaç: Kalp yetersizliği (KY) kılavuz önerilerinin klinik pratikte uygulanması zaman almaktadır ve genellikle gerçek yaşam şartlarında optimal düzeyde uygulanmamaktadır. Bu zorluğun önemli nedenlerinden biri hekim ile ilişkili faktörlerdir. Bu anket çalışmasının amacı, Türkiye’deki kardiyoloji uzmanlarının düşük ejeksiyon fraksiyonlu kalp yetersizliği (DEF-KY) tedavi tercihlerini belirlemektir. Yöntem: Anket çalışması 22 sorudan oluşmaktadır. Bu sorular, SurveyMonkey üzerinden yayınlanmış ve anket katılım linki birçok sosyal medya aracı üzerinden hekimlere ulaştırılmıştır. Bulgular: Anket çalışmasına Türkiye’de görev yapmakta olan 177 kardiyoloji uzmanı ve asistanı katıldı. Katılımcıların ortalama yaşı 39.5, %73.3’ü erkek, %38.7’si eğitim ve araştırma hastanelerinde görev yapmakta idi ve sadece %10.2’si kendisini KY uzmanı olarak tanımlamaktaydı. Katılımcıların %80.1’i, DEF-KY tanısı için sınır ejeksiyon fraksiyonu değerini %40 olarak kabul ettiklerini belirttiler. Hekimlerin %52.6’sı anjiyotensin reseptör-neprilisin inhibitörü (ARNi) tedavisini ‘‘en etkili KY tedavisi’’ olarak kabul ettiklerini belirtmelerine karşın, %62.7’si ilacın geri ödeme kısıtlılıkları ve fiyatı nedeniyle, DEF-KY tedavisine ARNi yerine anjiyotensin dönüştürücü enzim inhibitörü (ADEi) ile başlamak zorunda kaldıklarını belirttiler. Katılımcıların %52.3’ü tedaviye farklı bir KY ilaç sınıfını eklemenin, halihazırda kullanılan ilaçların dozunu arttırmaktan daha önemli olduğunu belirttiler. Hekimlerin %69.5’i yeni tanı KY hastalarında, hastane yatışı sırasında dört KY ilaç sınıfını aynı anda başlamanın mümkün olduğunu belirttiler. Buna karşın günlük pratiklerinde, sırasıyla ADEi/ARNI, beta–bloker, mineralokortikoid reseptör antagonisti ve sodyum-glukoz ko-transporter 2 inhibitörlerini başladıkları sıralı yaklaşımı daha çok tercih ettiklerini belirttiler. Sonuç: Bu anket çalışması, kılavuz önerileri ile gerçek yaşam uygulamaları arasında önemli farklılıklar olduğunu ortaya koymaktadır. Kılavuz önerilerinin, klinik pratikte uygulanabilmesi için sağlık sağlayıcıların gerekli önlemleri almalarına ve düzenlemeleri yapmalarına ihtiyaç vardır.
